Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Navigating A Patient Centered World: What Works, What Doesn’t

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients and patient foundations have become sophisticated players in the funding and translation of early stage medicines. Panelists at FasterCures’ Partnering for Cures conference shared some of the challenges that still remain in how patient groups and other stakeholders can best maximize partnership opportunities.

You may also be interested in...



Pfizer, Alliance For Lupus Research To Co-Fund Translational Projects

Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?

Onyx’s Myeloma Drug Kyprolis Fits ODAC’s View On Accelerated Approval

FDA’s Oncologic Drugs Advisory Committee overwhelmingly endorsed the second-generation proteasome inhibitor for accelerated approval in the relapsed/refractory population. Onyx’s reliance on a single-arm study was appropriate given the lack of treatment options in a heavily pre-treated population, said ODAC members, who also looked favorably upon the company’s advanced plans for confirmatory trials.

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel